Navigation Links
Genesys in Medical News

Hoffa, Cherry to Speak at Community Rally Supporting Genesys Nurses

Rally To Support Local 332 Nurses Negotiating With Genesys Regional Medical Center FLINT, Mich., May 13 /PRNewswire-USNewswire/ -- Teamsters General President Jim Hoffa and Michigan Lt. Gov. John Cherry will lead a rally Wednesday, May 14, 2008, to show community support for more than 1,00...

Cell Genesys to Present at the Cowen and Company and the Lehman Brothers Healthcare Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will present a company update on Tuesday, March 18 at 8:00 a.m. ET at the Cowen and Comp...

Cell Genesys Reports Fourth Quarter and Year-End 2007 Results

Conference Call Scheduled for 5:00 p.m. ET Today SOUTH SAN FRANCISCO, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today reported financial results for the fourth quarter and full year ended December 31, 2007. The company reported a net loss of $33....

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

Cell Genesys, Inc. (Nasdaq: CEGE) today announced follow-up data from a Phase 2 clinical trial of GVAX immunotherapy for pancreatic cancer which was conducted by the Johns Hopkins Sidney Kimmel Cancer Center. The trial enrolled 60 patients with operable pancreatic cancer who received GVAX after su...

Social Entrepreneur's Cup Finalists Announced

...s Today Leaders Forever and the 2008 Social Entrepreneur's Cup winner; and Jeff Tollefson, former venture capitalist and current Executive Director of genesys Works. The Social Entrepreneur's Cup finalists represent the spectrum of social needs including education, health, homelessness, and sustainable ...

Best Practices in Asia Pacific Healthcare and ICT Sectors Recognised

...ic Market Leadership F5 Networks Award in the Application Delivery Controller Market 2008 Asia Pacific Market Leadership genesys Telecommunications Award CTI Systems Market Laboratories 2008 Asia Pacific Market Leadership Aspect Software ...

Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinson's Disease

...former subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE ). The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell genesys as well as Hamilton BioVentures and California Technology Partners. ...

HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... 224436920.1 BioCryst Pharmaceutical Inc BCRX 216859123.5 Xoma Ltd (Bermuda) XOMA 735715935.4 Cell genesys Inc CEGE 542413535.1 Progenics Pharmaceuticals Inc PGNX 78957476.65 Gtx Inc GTXI...

New lung cancer vaccine on the anvil

...tudy is really good proof of principle that immune therapies can be translated from interesting lab findings into the treatment of patients. Cell genesys Inc., in Foster City, Calif., is developing the vaccine as a cancer treatment. The company is sponsoring phase II safety/efficacy clinical trials. ...
Genesys in Medical Technology

Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today reports the results of an analysis examining the potential association between immune responses to GVAX immunotherapy for prostate cancer and increased patient survival in a Phase 2 trial i...

Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., April 03, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic ...

Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response

SOUTH SAN FRANCISCO, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer f...

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

SOUTH SAN FRANCISCO, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced follow-up data from a Phase 2 clinical trial of GVAX immunotherapy for pancreatic cancer which was conducted by the Johns Hopkins Sidney Kimmel Cancer Center. The trial enrolled 60 patients with...

Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer

...that study is performed according to the SPA. Cell genesys completed the modifications requested by FDA durin... Conference Call and Webcast Members of the Cell genesys management team will host a conference call today,...ence call live on the investor section of the Cell genesys website, http://www.cellgenesys.com . Alternative...

Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease

...former subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE ). The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell genesys as well as Hamilton BioVentures and California Technology Partners. ...

ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents

... indicate that antiplatelet therapy is an important factor relating to the occurrence of stent thrombosis in DES patients," said Dr. Dobies, Director, genesys Heart Institute, Grand Blanc, Michigan. "Other significant predictors change from one to two years, suggesting differences in pathophysiology that may...
Genesys in Biological Technology

Cell Genesys to Present at the BIO CEO and Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the BIO CEO and Investor Conference in New York, New York, on ...

Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million

SOUTH SAN FRANCISCO, Calif., and GREENWICH, Conn., Dec. 20 /PRNewswire- FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) and GBP IP, LLC, an affiliate of GBP Capital, the majority shareholder in privately held Lentigen Corporation, today announced that the two companies have entered into an a...

Cell Genesys to Webcast Third Quarter 2007 Conference Call

SOUTH SAN FRANCISCO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ), today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer, and Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will host a conferen...

Cell Genesys to Present at the BIO Investor Forum

SOUTH SAN FRANCISCO, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ), today announced that Robert Dow, MBChB, chief medical officer of Cell Genesys, will present a company update on Wednesday, October 10, at 10:15 a.m. PT at the BIO Investor Forum being held in San...

Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ), today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will present a company update at the Bear Stearns 20th Annual Healthcare Conference in N...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...Medimmune, LLC, Bristol-Myers Squibb Company, Cell genesys Inc., Dendreon Corporation, EUSA Pharma, (USA) Inc... Bavituximab in Prostate Cancer II-54 Cell genesys Reveals Data of GVAX Immunotherapy for Treatment ...or New Prostate Cancer Compound II-71 Cell genesys Forms Global Alliance with Takeda on GVAX Immu...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...UTICS INC. (NASDAQ: ALTH ) ARQULE INC. (NASDAQ: ARQL ) ARRAY BIOPHARMA INC. (NASDAQ: ARRY ) BIOCRYST PHARMACEUTICALS INC. (NASDAQ: BCRX ) CELL genesys INC. (NASDAQ: CEGE ) DENDREON CORP (NASDAQ: DNDN ) DYNAVAX TECHNOLOGIES CORP (NASDAQ: DVAX ) GPC BIOTECH AG-ADR (NASDAQ: GPCB ) IMMUNOGEN INC....

Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team

... served as a member of the board of directors of Monogram Biosciences (MGRM), Inc., a publicly-traded biotechnology company; and the advisory board of genesys Capital, a venture capital firm. He is the author or inventor of over 40 publications and patents. Mendlein earned his Ph.D. in physiology and biophys...

Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer

... respectively. Ceregene was launched in January 2001, and the company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell genesys (Nasdaq: CEGE ), as well as Hamilton BioVentures and California Technology Partners. ...
Other Tags
(Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... from Montefiore Medical Center and the ... will present new findings at the Alzheimer,s Association International ... in Copenhagen, Denmark. Data from the four abstracts will ... normality to mild cognitive impairment and dementia. The research ... established in 1980 to examine healthy brain aging as ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
(Date:7/9/2014)... age with kidney and heart disease have raised concerns ... adults. However, in the first study to look closely ... Medicine at the University of Pennsylvania report that older ... expectancy and cardiovascular health as very healthy older people ... the ever increasing organ transplant waitlists, the authors of ...
Breaking Medicine News(10 mins):Health News:Wake-up call for more research into cell metabolism 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
(Date:7/9/2014)... Regulated deer hunts in Indiana state parks have helped ... damage caused by overabundant populations of white-tailed deer, a ... Michael Jenkins, associate professor of forest ecology, found that ... organizing hunts in state parks has successfully spurred the ... scarce by browsing deer. , Jenkins said that ...
(Date:7/9/2014)... Emerging fungal pathogens pose a greater threat to ... declines of amphibians, bats, corals, bees and snakes. ... published in the prestigious journal Nature ... resistance to a deadly chytrid fungus implicated in ... is important because it is the basis of ...
(Date:7/9/2014)... Cancer Genome Atlas (TCGA) Research Network have identified ... lung adenocarcinoma, the most common subtype of lung ... the number of possible therapeutic targets for this ... patients with treatable mutations because many potent cancer ... TCGA is jointly funded and managed by the ...
Breaking Biology News(10 mins):Hunting gives deer-damaged forests in state parks a shot at recovery 2USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
Other Contents